Viking Therapeutics Inc

Stock Chart, Company Information, and Scan Results

$37.18(as of Dec 26, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Viking Therapeutics Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$37.18
Ticker SymbolVKTX
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees50
CountyUSA
Market Cap$4,202.7M
EBIDTAUnknown
10-Day Moving Average35.87
P/E Ratio-17.59
20-Day Moving Average36.33
Forward P/E Ratio0.00
50-Day Moving Average36.18
Earnings per Share-2.12
200-Day Moving Average30.34
Profit Margin-Infinity%
RSI54.85
Shares Outstanding113.0M
ATR1.84
52-Week High43.55
Volume1,633,160
52-Week Low18.92
Most Recent Support Level33.89
Book Value713.0M
Most Recent Resistance Level37.83
P/B Ratio5.86
Upper Keltner40.48
P/S RatioInfinity
Lower Keltner32.17
Debt-to-Equity Ratio40.48
Next Earnings Date02/11/2026
Cash Surplus74.3M
Next Ex-Dividend DateUnknown

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

Viking Therapeutics Inc In Our Stock Scanner

As of Dec 29, 2025
example chart graphic
Scan Name: Dragonfly DojiScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Doji CandlesScan Type: Candlestick Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.

This site uses cookies to provide you with an optimal user experience. By using StockMarketGuides.com, you accept our use of cookies.